New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Minjuvi ® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with...